Tuesday, 17 September 2024
  
Login

Australia's most trusted
source of pharma news

Tuesday, 17 September 2024
Listen to this story 
News

When is it safe to jump ship?

Posted 11 September 2024 AM

The Australian biopharma space is seeing significant success, but even so there is the ever-present risk of drugs failing before they're medicines are commercialised. So when is it safe to make the jump from Big Pharma to a local company?

"The stage where most of the attrition happens is in phase two, where the likelihood of going from phase two into phase three is way less than 50 per cent," OneVentures founding partner, Dr Paul Kelly, told Pharma in Focus. OneVentures is a venture capital firm with a strong history supporting healthcare and biotech innovations.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (18)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (5)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.